Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
\-- MRT5005 is the first clinical-stage mRNA therapeutic with nebulized delivery to the lung and first to be administered in multiple doses for the treatment of a chronic genetic disease -- \-- Completed enrollment and dosing for upcoming second interim data analysis; includes 8, 12 and 16 mg multiple-ascending dose groups and 20 mg single-ascending dose group --LEXINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics c...
LEXINGTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, announced today that John Schroer, the Company’s Chief Financial Officer (CFO), is departing the Company for personal reasons. Mr. Schroer's departure will be effective by year-end 2020. Robert Prentiss, Translate Bio’s Vice Presiden...
Moderna has emerged as a strong competitor in the race for a coronavirus vaccine. But Moderna stock remains on a wild ride in 2020 as the need for a Covid-19 vaccine grows.
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
Messenger RNA (mRNA) coronavirus vaccine candidates now appear to be batting two for two. Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announced great interim efficacy results for their experimental mRNA COVID-19 vaccine last week. Are there other biotech stocks with mRNA vaccine programs that could also be winners?
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that the Company will participate in the following upcoming investor conferences: * Jefferies Virtual London Healthcare Conference: John Schroer, chief financial officer, will present a corporate overview at the Jeff...
Pfizer stock rocketed early Monday after the pharma giant said its coronavirus vaccine was more than 90% effective in a Phase 3 study. Pfizer briefly topped a buy point from a flat base.